Protein Design Labs starts Phase II in NHL

PDLI began open-label Phase II testing of its SMART 1D10 humanized antibody against 1D10 HLA-DR determinant in 60 patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) to study the ...